Tonix Pharma stock analysis
Tonix Pharma (TPM0) Stock Price & Analysis
TPM0 Stock Chart & Stats
- Day’s Range
- EUR 2.47 - EUR 2.47
- 52-Week Range
- EUR 2.32 - EUR 17.00
- Previous Close
- EUR 2.35
- Volume
- N/A
- Average Volume (3M)
- 4
- Market Cap
- EUR 45.16M
- Enterprise Value
- EUR 18.07M
- Total Cash (Recent Filing)
- EUR 162.79K
- Total Debt (Recent Filing)
- EUR 1,253
- Price to Earnings (P/E)
- ―
- Beta
- 0.49
- Next Earnings
- Mar 15, 2027 (Est.)
- EPS Estimate
- -2.33
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Rapid Revenue Growth And High Gross Margin
TTM revenue rose from $13.1M in 2025 to $43.0M, while gross margin reached about 86.9%. This combination shows TONMYA-driven commercialization is adding meaningful scale and leaves substantial gross profit per dollar of sales, creating a platform for future operating leverage if growth persists.
TONMYA Commercial Traction
TONMYA has demonstrated repeatable commercial adoption: Q3 sales grew 37% QoQ, prescriptions 28%, and refills 56%, while coverage reached 53% of covered lives. Expanding payer access and prescriber reach can support recurring demand and improve the product’s durability beyond an initial launch spike.
Advancing Clinical Pipeline
FDA agreement on the adaptive Phase II TNX-4800 design, planned enrollment of about 3,300 adults, and manufacturing and CRO preparation establish a defined path for a significant clinical program. This advances pipeline diversification and preserves longer-term upside beyond TONMYA.
Bears Say
Severe Operating Losses And Cash Burn
TTM EBIT was -$187.8M, operating cash flow -$165.3M, and free cash flow -$170.0M. Persistent losses at this scale consume resources despite revenue growth, reduce internally funded investment capacity, and make continued external financing important for sustaining development and commercialization.
TONMYA Patent Litigation Risk
Dr. Reddy’s Paragraph IV filing challenges four TONMYA patents, forcing Tonix into litigation to defend the branded franchise. Although the complaint triggered a potential 30-month stay, the dispute creates durable uncertainty around exclusivity, future competition, and the value of TONMYA’s revenue stream.
Elevated Commercialization Costs
SG&A increased sharply to $45.6M from $25.7M, and management expects the sales force to remain a significant cost as TONMYA expands. These elevated commercialization expenses can delay operating leverage and intensify cash consumption if revenue growth does not outpace launch spending.
Tonix Pharma News
TPM0 FAQ
What was Tonix Pharma’s price range in the past 12 months?
What is Tonix Pharma’s market cap?
When is Tonix Pharma’s upcoming earnings report date?
How were Tonix Pharma’s earnings last quarter?
Is Tonix Pharma overvalued?
Does Tonix Pharma pay dividends?
What is Tonix Pharma’s EPS estimate?
How many shares outstanding does Tonix Pharma have?
What happened to Tonix Pharma’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Tonix Pharma?
What is the TipRanks Smart Score and how is it calculated?
Tonix Pharma Stock Smart Score
Company Description
Tonix Pharma
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its headquarters in Chatham, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Seth Lederman
- Employees
- 142
- Website
- www.tonixpharma.com
- Address
- 200 Connell Drive, Berkeley Heights, NJ, 07928, US
Tonix Pharma (TPM0) Earnings & Revenues
TPM0 Company Deck
TPM0 Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive, led by strong TONMYA sales and prescription growth, improving payer coverage, rising refills, expanded commercial reach, and continued progress across the clinical pipeline. The main challenges were the Dr. Reddy's Paragraph IV patent challenge, materially higher operating expenses, a declining cash balance, uncertainty around some clinical timelines, and the regulatory impasse for TNX-1300.
View all DE:TPM0 earnings summariesTPM0 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 0 | 16 |
| Technical Analysis | 6 | 0 | 4 |
| Moving Averages | 0 | 0 | 12 |














